. 2005; 22(4): 161-172 | |||
Imatinib mesylate and the management of chronic myeloid leukemia (CML)Ebru Koca, İbrahim C. HaznedaroğluDepartment Of Internal Medicine, Hematology Unit, Hacettepe University School Of Medicine, Ankara, TurkeyKeywords: Chronic myeloid leukemia (CML), Imatinib mesylate, BCR-ABL, Signal transduction inhibitor. Ebru Koca, İbrahim C. Haznedaroğlu. Imatinib mesylate and the management of chronic myeloid leukemia (CML). . 2005; 22(4): 161-172 Sorumlu Yazar: İbrahim C. Haznedaroğlu, Türkiye |
|